Fig. 6: The combined inhibition of BTK and SYK produces synergistic lethality in MYD88-mutated lymphoma cells.
From: SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
Evaluation for the combination of ibrutinib with the SYK inhibitors tamatinib (R406) (a, b) or entospletinib (GS-9973) (c, d) was undertaken in MYD88-mutated WM (BCWM.1, MWCL-1) and MYD88/CD79B mutated ABC DLBCL (TMD8, HBL-1) cells. The findings from combination index (CI) and normalized isobologram analyses are depicted. CI<1 or the dots under the oblique line in the isobologram plots indicate a synergistic effect for the combination (a–d). Studies were performed twice, and representative experimental set is shown.
